Drug Trial Radar · NCT07931521
Clinical Trial to Evaluate the Safety and Efficacy of DW4421 in Patients With Erosive Reflux Disease
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
328
Actual
Start
Nov 17, 2025
Primary completion
Aug 31, 2026
Study completion Sep 14, 2026
Sponsor
- Lead sponsor
- Daewon Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to compare the efficacy and safety of DW4421 to Esomeprazole in patients with Erosive Reflux Disease.
Conditions
- Erosive Reflux Disease
- GERD (Gastroesophageal Reflux Disease)
Interventions
DW4421 20mgDrug
DW4421 20mg 1Tab. + DW4421 40mg placebo 1Tab. + Esomeprazole 40mg placebo 1Tab., once daily, PO
DW4421 40mgDrug
DW4421 20mg placebo 1Tab. + DW4421 40mg 1Tab. + Esomeprazole 40mg placebo 1Tab., once daily, PO
Esomeprazole 40mgDrug
DW4421 20mg placebo 1Tab. + DW4421 40mg placebo 1Tab. + Esomeprazole 40mg placebo 1Tab., once daily, PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative healing rate of mucosal break evaluated by BICR (Blind Independent Central Review) at Week 8 after administration of the investigational product (%)Time frame: Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Catholic University of Korea, Incheon, St. Mary's Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.